Abbott Laboratories (ABT)
| Market Cap | 193.60B |
| Revenue (ttm) | 45.55B |
| Net Income (ttm) | 8.55B |
| Shares Out | 1.75B |
| EPS (ttm) | 4.79 |
| PE Ratio | 23.08 |
| Forward PE | 22.52 |
| Dividend | $1.86 (1.68%) |
| Ex-Dividend Date | Jul 14, 2022 |
| Volume | 3,052,893 |
| Open | 111.63 |
| Previous Close | 112.03 |
| Day's Range | 110.37 - 112.13 |
| 52-Week Range | 101.24 - 142.60 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 130.47 (+18.0%) |
| Earnings Date | Jul 20, 2022 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipi... [Read more...]
Financial Performance
In 2021, ABT's revenue was $43.08 billion, an increase of 24.47% compared to the previous year's $34.61 billion. Earnings were $7.07 billion, an increase of 57.31%.
Financial StatementsAnalyst Forecast
According to 27 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is 130.47, which is an increase of 18.02% from the latest price.
News
Should Dividend Investors Add This Stock to Their Portfolios?
This Dividend King pays shareholders a market-beating dividend.
Abbott to add 1,000 jobs in $450 million Irish investment
U.S. healthcare company Abbott Laboratories plans to hire 1,000 more people in Ireland in one of the biggest job announcements this year in the country's booming multinational sector, state investment a...
2 Healthcare Stocks That Could Help Set You Up for Life
Whether your goal is building generational wealth or simply achieving financial independence, buying these two stocks could be worth your while.
2 Dividend Kings That Have Hiked Their Payouts by More Than 50% in 5 Years
These companies aren't stingy when it comes to making rate hikes.
New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Inte...
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care Researc...
Should You Really Care About This Company's Short-Term Success?
Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.
Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals
Two industry leaders join forces to empower people living with diabetes by providing information and insights to improve weight loss, glucose control and overall health Collaboration will create a seaml...
Final Trades: TJX, Qualcomm, Abbott Labs & more
The "Halftime Report" traders give their top picks to watch for the second half.
3 Dividend Aristocrats to Buy in August
These stocks have reliable dividends and strong underlying businesses.
Is Abbott Laboratories a Buy?
This stock rewards investors who have patience.
Why a Product Recall Won't Change This Company's Prospects
This company's business won't fail that easily.
2 Surefire Dividend Stocks That Are Laughing Off Inflation
Their dividends tend to grow much faster than the inflation rate in the long run.
Is Abbott Laboratories stock a ‘buy' after market-beating Q2 results?
Abbott Laboratories (NYSE: ABT) down more than 20% for the year is an opportunity to buy a quality name at a deep discount, says Brenda Vingiello. She's the Chief Investment Officer at Sand Hill Global ...
Final Trades: Boeing, Invitation Homes, Abbott Labs & more
The "Halftime Report" traders give their top picks to watch for the second half.
Abbott's (ABT) Q2 Earnings Top Estimates, '22 EPS View Up
Abbott (ABT) reports better-than-expected results for Q2 2022, with robust contributions from the Established Pharmaceuticals, Diagnostics and Medical Device segments.
Abbott is now aiming to recover the baby-formula market share that it lost
Abbott Laboratories ABT, -1.35% is focused on recovering its position in the baby-formula market in the U.S. following the recall that required the intervention of the Biden administration to ensure tha...
Abbott earnings top estimates as baby formula losses offset by COVID test sales
Yahoo Finance medical reporter Anjalee Khemlani breaks down second-quarter earnings for Abbott Laboratories.
Abbott Laboratories (ABT) Stock Slides Despite Q2 Earnings Beat
Abbott Laboratories (ABT) stock is falling on Wednesday despite posting a positive earnings report for the second quarter of 2022. The post Abbott Laboratories (ABT) Stock Slides Despite Q2 Earnings Bea...
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Abbott (ABT) delivered earnings and revenue surprises of 31.19% and 8.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Abbott Lifts Annual Profit Guidance On Higher COVID-19 Test Sales
Abbott Laboratories (NYSE: ABT) has reported Q2 FY22 adjusted EPS of $1.43, up 22.2% Y/Y, better than the consensus of $1.12. Q2 sales of $11.3 billion increased 10.1% on a reported basis and 14.3% on a...
What's Going On With Abbott Stock Today?
Abbott Laboratories (NYSE: ABT) shares are trading lower Wednesday after the company reported financial results. Abbott said second-quarter revenue increased 10.1% year-over-year to $11.3 billion, which...
Abbott Laboratories shares fall in premarket despite second-quarter earnings beat
Shares of Abbott Laboratories ABT, +2.72% fell 2.85% to $106.8 in premarket trading Wednesday although the company beat second-quarter earnings and sales estimates, fueled by sales of its COVID-19 tests...
Abbott Laboratories Posts Better-Than-Expected Q2 Sales, Earnings
Abbott Laboratories on Wednesday topped estimates for second-quarter sales and earnings and guided higher for the full year. The post Abbott Laboratories Posts Better-Than-Expected Q2 Sales, Earnings ap...